SKIN Stock Forecast & Price Target

SkinHealth Systems is supported by a resilient, recurring revenue model, with about 75% of revenue tied to consumables and an active installed base that grew to 36,516 systems, up ~4% y/y. Although 2Q26 revenue fell 8% y/y to $72.1M as Delivery Systems weakened and provider financing constraints persisted, adj. EBITDA of $17M meaningfully beat expectations, helped by gross margin expansion to 71.8% and disciplined expense control. Management’s new U.S. rental program, HydraScalp relaunch, and ~50% y/y SkinStylus growth, alongside FY26 EBITDA guidance raised to $39-45M, suggest credible levers for improving utilization and future growth.

SkinHealth Systems is facing a weak fundamental setup because revenue guidance was cut to $280 million-$295 million for 2026, while device demand remains under pressure with Delivery Systems down 18% y/y and consumables down 4% y/y in 2Q. Management’s ability to translate 770 placements into only 97 net additions to the active install base suggests churn and low utilization are offsetting gross sales, which limits confidence in a durable growth recovery. Although the company’s ~$206 million cash balance exceeds its ~$91 million market cap, the ~$250 million November 2028 convertible maturity, ongoing litigation, and regulatory risk still create a meaningful balance-sheet and cash-flow overhang.